D.Y.C. Heng

1.2k total citations
55 papers, 927 citations indexed

About

D.Y.C. Heng is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, D.Y.C. Heng has authored 55 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 21 papers in Cancer Research and 20 papers in Oncology. Recurrent topics in D.Y.C. Heng's work include Renal cell carcinoma treatment (44 papers), Cancer Genomics and Diagnostics (19 papers) and Renal and related cancers (16 papers). D.Y.C. Heng is often cited by papers focused on Renal cell carcinoma treatment (44 papers), Cancer Genomics and Diagnostics (19 papers) and Renal and related cancers (16 papers). D.Y.C. Heng collaborates with scholars based in Canada, United States and Denmark. D.Y.C. Heng's co-authors include Toni K. Choueiri, Christian Kollmannsberger, Brian I. Rini, Georg A. Bjarnason, Frede Donskov, Lori Wood, Ulka N. Vaishampayan, Scott North, Mary J. MacKenzie and Jennifer J. Knox and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

D.Y.C. Heng

55 papers receiving 916 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D.Y.C. Heng Canada	18	652	400	372	314	98	55	927
Aline Guillot France	16	692 1.1×	426 1.1×	315 0.8×	330 1.1×	206 2.1×	62	1.0k
Carole Hélissey France	14	558 0.9×	163 0.4×	527 1.4×	197 0.6×	126 1.3×	81	1.1k
Hadar Goldvaser Israel	15	185 0.3×	236 0.6×	450 1.2×	381 1.2×	83 0.8×	71	899
Jonathan J. Wilson Canada	4	1.0k 1.6×	153 0.4×	506 1.4×	296 0.9×	121 1.2×	8	1.3k
Thomas J. Semrad United States	15	237 0.4×	257 0.6×	395 1.1×	162 0.5×	122 1.2×	51	890
Stephen B. Riggs United States	17	989 1.5×	674 1.7×	324 0.9×	350 1.1×	408 4.2×	50	1.4k
Sanjaykumar Hapani United States	6	362 0.6×	216 0.5×	577 1.6×	85 0.3×	158 1.6×	9	1.0k
Alyssa Klein United States	11	372 0.6×	180 0.5×	331 0.9×	106 0.3×	155 1.6×	28	754
Andrew A. Renshaw United States	14	1.2k 1.8×	243 0.6×	191 0.5×	206 0.7×	287 2.9×	21	1.5k
Mustapha Tehfé Canada	17	656 1.0×	186 0.5×	699 1.9×	145 0.5×	241 2.5×	90	1.1k

Countries citing papers authored by D.Y.C. Heng

Since Specialization

Citations

This map shows the geographic impact of D.Y.C. Heng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D.Y.C. Heng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D.Y.C. Heng more than expected).

Fields of papers citing papers by D.Y.C. Heng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D.Y.C. Heng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D.Y.C. Heng. The network helps show where D.Y.C. Heng may publish in the future.

Co-authorship network of co-authors of D.Y.C. Heng

This figure shows the co-authorship network connecting the top 25 collaborators of D.Y.C. Heng. A scholar is included among the top collaborators of D.Y.C. Heng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D.Y.C. Heng. D.Y.C. Heng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Labaki, Chris, Juan Gallegos, Dustin McCurry, et al.. (2023). 1891P Determinants of exceptional response to immune checkpoint inhibition in metastatic clear cell renal cell carcinoma. Annals of Oncology. 34. S1017–S1017. 1 indexed citations

Yip, Steven, Michael Kolinsky, Kosuke Takemura, et al.. (2023). 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi). Annals of Oncology. 34. S972–S972. 1 indexed citations

Navani, Vishal, T.B. Powles, Luís Meza, et al.. (2023). 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. Annals of Oncology. 34. S1018–S1019. 1 indexed citations

Wells, J. Connor, Shaan Dudani, Gan Chen, et al.. (2020). Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma. European Urology Open Science. 19. e1105–e1106. 1 indexed citations

Chen, Gan, Daniel E. Meyers, Igor Stukalin, et al.. (2020). 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents. Annals of Oncology. 31. S1408–S1408. 2 indexed citations

Wong, Emily C L, Rodney H. Breau, Ranjeeta Mallick, et al.. (2019). Renal Cell Carcinoma in the Canadian Indigenous Population. Current Oncology. 26(3). 367–371. 2 indexed citations

Kushnir, Igal, Ranjeeta Mallick, Raymond H. Kim, et al.. (2019). Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database. Clinical Oncology. 32(1). e10–e15. 5 indexed citations

Francini, Edoardo, Steven Yip, Neesar Ahmed, et al.. (2017). Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry. Annals of Oncology. 28. v278–v279. 3 indexed citations

Harshman, Lauren C., Charles G. Drake, Naomi B. Haas, et al.. (2017). Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward. PubMed. 1(1). 31–40. 6 indexed citations

10.

Cella, David, Bernard Escudier, Nizar M. Tannir, et al.. (2016). Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC). Annals of Oncology. 27. vi284–vi284. 3 indexed citations

11.

Lalani, Aly‐Khan A., D.Y.C. Heng, Lori Wood, et al.. (2016). Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology. 27. vi285–vi285. 3 indexed citations

12.

Kheoh, Thian, Charles J. Ryan, A. Molina, et al.. (2015). A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Annals of Oncology. 27(3). 454–460. 132 indexed citations

13.

Jiang, Di, Soundouss Raissouni, Anjali S. Kumar, et al.. (2015). Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer. Annals of Oncology. 26(10). 2102–2106. 22 indexed citations

14.

Ko, Jenny J., Toni K. Choueiri, Brian I. Rini, et al.. (2014). First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. British Journal of Cancer. 110(8). 1917–1922. 58 indexed citations

15.

Heng, D.Y.C., Toni K. Choueiri, Brian I. Rini, et al.. (2013). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology. 25(1). 149–154. 113 indexed citations

16.

Kaymakcalan, Marina D., Youjin Je, Guru Sonpavde, et al.. (2013). Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. British Journal of Cancer. 108(12). 2478–2484. 31 indexed citations

17.

Heng, D.Y.C., Wanling Xie, Lauren C. Harshman, et al.. (2011). External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy.. Journal of Clinical Oncology. 29(15_suppl). 4560–4560. 13 indexed citations

18.

Rini, Brian I., Lauren C. Harshman, Georg A. Bjarnason, et al.. (2011). The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts).. Journal of Clinical Oncology. 29(15_suppl). 4555–4555. 14 indexed citations

19.

Heng, D.Y.C., Mary J. MacKenzie, Ulka N. Vaishampayan, et al.. (2011). Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy.. Journal of Clinical Oncology. 29(7_suppl). 305–305. 21 indexed citations

20.

Choueiri, Toni K., Christian Kollmannsberger, Scott North, et al.. (2011). Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.. Journal of Clinical Oncology. 29(7_suppl). 318–318. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact